Introduction to the I Know First predictive algorithm.
How to read and use the algorithmic forecast signals.
Examples of stock picking strategies and trading methods.
The I Know First algorithm is an advanced tool for identifying opportunities in any given market situation. Not only does it detect opportunities for buying stocks (long positions) but also for selling them (short positions). Given the predictive power of the algorithm's forecast, does this mean that you should buy any stock that it recommends? Of course not! To figure out what trades to make, we need to employ stock picking strategies and trading methods.
COVID-19 number of cases is increasing and, no signs of stopping;
Automotive and airline companies may take the biggest hit in 2020;
Medical and biotech stocks are the opportunities in this situation;
Netflix and other streaming services can benefit from the outbreak.
Background
Due to Corona-virus (COVID-19) infectiousness characteristics, the disease started spreading globally since December 2019 despite the efforts made by Chinese government. On February 27, the World Health Organization published a report announcing that over 81,000 cases of the disease were confirmed, with 78,000 being in China. The number of deaths worldwide exceeded 3,300, with almost 300 of them outside China. With Brazil confirming its first case
The article was written by Motek Moyen ResearchSeeking Alpha’s #1 Writer on Long Ideas and #2 in Technology – Senior Analyst at I Know First.
Summary:
Tesla remains the leader in electric cars. Two or three years from now, I expect Tesla to also lead in high-end electric motorcycles.
Car vendor Honda is selling more than 19 million units of regular motorcycles per year. Honda has upcoming electric motorcycles.
More than 130 million units of motorcycles are sold annually. Almost 109 million of them sold in the Asia Pacific Region.
It is faster to assemble Tesla electric motorcycles than cars and trucks. Tesla can improve its bottom line by the quicker turnaround of selling motorcycles.
TSLA has a very bullish one-year forecast from I Know First. It might be wise to load up on this stock while it trades below $370.
“No One Can Take Our Smiles Away When Dental Decay is Kept Miles Away” – Pro. Dr. Ninad Moon
Summary • 3D Systems Q1 results of 2018 • ‘NextDent’ 5100 – 2018 Healthcare Application of the year • I Know First Bullish Forecast for DDD
3D Systems Corporation, through its subsidiaries, provides three-dimensional (3D) printing products and services worldwide. The company offers 3D printers, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, and color jet printers that transform data input generated by 3D design software, CAD software, or other 3D design tools into printed parts under the Accura, DuraForm, LaserForm, CastForm, and VisiJet brand names. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental, and Class IV bio-compatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as products for product design, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection. Further, it offers proprietary software and drivers that provide part review, part preparation, part placement, automated support building and placement, build platform management, and print queue management; and 3D virtual reality simulators and simulator modules for medical applications, as well as digitizing scanners for medical and mechanical applications. Additionally, the company provides warranty, maintenance, and training services; on-demand manufacturing solutions; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable good, government, defense, technology, jewelry, electronic, education, consumer good, energy, and other industries through direct sales force, as well as partner channels and distributors. The company was founded in 1986 and is headquartered in Rock Hill, South Carolina.
Q1 results of 2018 On May 2, 2018 3D Systems Corporation announced its Q1 report of 2018. Among the items of the report the revenue growth of 6% to $165.9 million compared to $156.4 million in Q1 of 2017 should draw investors’ attention in a positive direction to see that the company is on a growing path for the long term. Specifically, one could see 24% higher printer revenue on 44% higher printer unit sales, as well as sales growth in software, on demand manufacturing and healthcare solutions. However, the company’s GAAP operating expenses showed an increase of $95.4 million compared to $89.3 million in the prior year period. The result is that the company received non-GAAP loss of $0.03 per share compared to non-GAAP earnings of $0.06 per share in Q1 of 2017. The raise in the company’s total cost of sales to $88,006 compared to $76,245 in the prior year period and in the company’s investments in R&D is part of what caused the decrease in the company’s stock price per share for Q1 of 2018. Although, I still believe 3D Systems will grow in the long term and be among the top beneficiaries of 3D printing revolution in the upcoming future. Finally, during this quarter, the company used $1.5 million of cash in operations and ended with $121.6 million of unrestricted cash on hand.
[Image Source: 3DSystems.com]
‘NextDent’ 5100 – 2018 Healthcare Application of the year
[Image Source: 3DSystems.com]
On May 21, 2018 ‘NextDent’ 5100 (digital dentistry solution) was announced that it was awarded the 2018 healthcare application of the year by the publication ‘3D Printing Industry’. ‘NextDent’ 5100 was revealed on February 22, 2018. The ‘NextDent’ 5100 redefines digital dentistry and enables enhanced patient care. It is powered by Figure 4 technology- configurable assembly of interconnected SLA printers for mass production of custom parts and products. It is also being proposed as a platform for traditional manufacturers to bring their production facility to the digital era. In addition, it out-performs similar competitive offerings with 4 times the speed. By including the ‘NextDent’ 5100 into their workflow, dental laboratories and clinics of all sizes are able to address, for the first time, more conditions that cause pain or discomfort and potentially endanger a patient’s life or health with one solution. Cost-wise, 3D-printed dentures and orthodontist braces could be more cost-efficient than handcrafted.
Selling the ‘NextDent’ 5100 benefits 3D Systems in the digital dentistry. The acquisition of NextDent last year gave 3D Systems more than 18 biocompatible materials which it can sell to dentists and dental clinics. Like other printers, the bigger money is in supplying the materials. Dentists and dental clinics who purchase a 3D printer could become repeat customers for dental materials for many years. As shown below, dental 3D printing market revenue is growing extensively with time and is expected to continue in this path due to rising prevalence of dental caries and increase in incidence of tooth loss owing to injury and accident.
DDD stock increased by 19.34% since the Q1 results of 2018 were announced. My conclusion is that DDD stock will continue to grow in the long term given the fact that the 3D printing revolution has not arrived yet but when it does, 3D Systems will be among the top beneficiaries. ‘NextDent’ 5100 is not only a digital dentistry solution but also a revolutionary innovation.
[Image Source: Yahoo Finance]
According to analyst recommendations from Yahoo Finance, the current consensus is a “Hold” in 3D Systems Stock, with 10 advising.
[Image Source: Yahoo Finance]
Current bullish I Know First Algorithm forecast for DDD
3D printing is an upcoming revolution in the future. So, investing in 3D Systems, going long and holding, is a good course of actions as for now. I Know First Algorithm is currently bullish for DDD stock which appears to be bullish for 1, 3 and 12 months investment horizons.
Past I Know First Algorithm forecast success with DDD
On February 23, 2018 I Know First has made an accurate prediction for DDD. With bullish signal of 25.09 and predictability indicator of 0.57 (see heat map explanation below) DDD is with about 27.43% gain since this bullish forecast. This bullish forecast for DDD sent to the current I Know First subscribers on February 23, 2018.
I Know First Algorithm Heat-map Explanation
This indicator represents the predicted movement direction/trend. The signal strength indicates how much the current price deviates from what the system considers a balance or “fair” price. The signal strength is the absolute value of the current prediction of the system. The signal can have a positive (increase), or negative (drop) sign. The heat map is arranged according to the signal strength with strongest up signals at the top. The table colors are indicative of the signal. Green indicates to the positive signal and red indicates a negative signal. A deeper color means a stronger signal and a lighter color equals a weaker signal. The sign of the signal tells in which direction the asset price is expected to go (positive = to go up = Long, negative = to drop = Short), the signal strength is related to the magnitude of the expected return and is used for ranking purposes of the investment opportunities. Predictability measures the importance of the signal. The predictability is the historical relationship between the prediction and the actual market movement for that particular market. For each asset this indicator is recalculated daily. Theoretically the predictability ranges from minus one to plus one. The higher this number is the more predictable the particular asset is. In comparison to different time ranges, predictability will be higher for longer time. This means that longer-range signals are more accurate. Predictability is a unique indicator of the I Know First algorithm which allows users to focus on the most predictable assets according to the algorithm. One should focus on predictability levels significantly above 0 in order to trust the signal, when ranging between -1 and 1.
“We made significant progress on multiple fronts executing our new business strategy, and in doing so we completely transformed the Company. The highlight events were clearly the license agreements we secured for both gevokizumab and our IL-1 beta intellectual property portfolio with Novartis. Our strategy was further reinforced with new license agreements for use of our proprietary phage display libraries for antibody discovery.”
– Jim Neal, Chief Executive Officer of XOMA
[Image Source: http://www.scienceimage.csiro.au/image/2057, from Wikimedia Commons]
Over the last 12 months, the market has witnessed a huge surge of XOMA’s stock by 269.14%. The result can be illustrated in the below chart:
The remarkable gain of XOMA can be attributed to the strong performance of the company in Q2 and Q3 2017. In Q2 2017, XOMA reached the $10 million milestone due to the license agreement with Novartis (NYSE: NVS). Additionally, thanks to the XOMA 052 License Agreement and IL-1 Target License Agreement with Novartis, XOMA has recognized $35.4 million revenue in license and collaborative fee in Q3 2017. As a result, over the last 5 quarters, Q2 and Q3 2017 are the only two quarters with a positive net income, $0.285 million and $26.344 million respectively.
(Source: financials.morningstar.com)
On May 25, 2017, I Know First has issued a bullish 1-year prediction for XOMA Corporation with the signal of 84.71 and the predictability of 0.52. One year later, XOMA shot up to $24.88 (269.14% upside), in line with our forecast.
Current I Know First subscribers received this bullish ESND forecast on May 25, 2017.
XOMA Corporation (NASDAQ: XOMA) is a biotechnology company located in Delaware. The company uses its own unique platform of antibody technologies to discover and develop innovative therapeutics. XOMA’s business model is to license its therapeutic assets to other corporations, which is later responsible for later development, approval, or commercialization. Moreover, the company has also licensed its platform of antibody technologies to other companies who want to make their own discovery efforts. The main customers of XOMA include pharmaceutical and biotech companies such as Novartis International Pharmaceutical Ltd. (“Novartis), Novo Nordisk AS (“Novo Nordisk”), Takeda Pharmaceutical Company Ltd. (“Takeda”), etc. Besides that, other companies also funded more than 20 programs of XOMA, which will generate milestone and royalty payments in the future. XOMA’s asset base includes different antibodies with unique properties. These antibodies are designed to either enhance or diminish a target protein’s activity. In February 2017, XOMA achieved initial proof-of-concept (“POC”) for its X358 clinical program. In the future, the company aim to maximize the value of X358 through licensing agreements with its partners. Moreover, XOMA will focus more on developing and acquiring revenue generating assets and coupling them with the current infrastructure. XOMA also expects that the payments from the licensees will contribute a significant portion of its future revenue.
Disclaimer
Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
